Sas, David J.
Harris, Peter C.
Milliner, Dawn S.
Article History
Received: 14 October 2018
Accepted: 8 November 2018
First Online: 10 December 2018
Change Date: 13 October 2019
Change Type: Correction
Change Date: 13 October 2019
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. On page 84, the dose for oral potassium citrate is incorrectly written as “0.1 mg/kg/day divided BID-QID for children, 30–60 mg per day divided BID-QID for adults”.
Change Details: The original version of this article unfortunately contained a mistake. On page 84, the dose for oral potassium citrate is incorrectly written as ���0.1��mg/kg/day divided BID-QID for children, 30���60��mg per day divided BID-QID for adults���.
Compliance with ethical standards
:
: Dr. Sas has not conflicts of interest. Dr. Harris has a research grant from Otsuka Pharmaceuticals and consulting agreements (funds to his research program) with Mitobridge, Vertex, and Regulus. Dr. Milliner has conducted research funded in part or in whole by OxThera, Allena, and Alnylam pharmaceutical companies. She has consulting contracts (funds to her research program) with OxThera, Alnylam, and Dicerna for general consulting and and/or as chair of a Data Safety Monitoring Board for a clinical trial.